Back
Compare AU
Compare DRUG vs. RSSL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Global X Russell 2000 ETF (RSSL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | RSSL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 7 |
Median incremental investment | $755.79 | $510.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,059.20 | $2,351.72 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | RSSL | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | RSSL.AX was created on 2025-02-10 by Global X. The fund's investment portfolio concentrates primarily on small cap equity. The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the Russell 2000 RIC Capped Index. |
Top 3 holdings | GBP - BRITISH POUND (0 %) DKK - DANISH KRONE (0 %) MYR - MALAYSIAN RINGGIT (0 %) | Credo Technology Group Holding Ltd (1.86 %) Bloom Energy Corp Class A (1.67 %) Fabrinet (1.49 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.57 % | 0 % |
Key Summary
DRUG | RSSL | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Russell 2000 RIC Capped Index - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0 % |
Price | $8.79 | $10.32 |
Size | $179.225 million | $5.832 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.97 % | 0.27 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 11/02/2025 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | RSSL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 7 |
Median incremental investment | $755.79 | $510.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,059.20 | $2,351.72 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | RSSL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | RSSL |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |